FBR Capital Raises Price Target on Evolent Health (EVH) to $24 Following Valence Health Acquisitions
Tweet Send to a Friend
FBR Capital reiterated an Outperform rating on Evolent Health (NYSE: EVH), and raised the price target to $24.00 (from $16.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
